-
1
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
-
2
-
-
84883745765
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
-
EXAMINE Investigators
-
White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., EXAMINE Investigators, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335.
-
(2013)
N Engl J Med
, vol.369
, pp. 1327-1335
-
-
White, W.B.1
Cannon, C.P.2
Heller, S.R.3
Nissen, S.E.4
Bergenstal, R.M.5
Bakris, G.L.6
-
3
-
-
84883765959
-
SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
-
(2013)
N Engl J Med
, vol.369
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
Steg, P.G.4
Davidson, J.5
Hirshberg, B.6
-
4
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
-
Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
-
(1996)
Control Clin Trials
, vol.17
, Issue.1
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
Jenkinson, C.4
Reynolds, D.J.5
Gavaghan, D.J.6
-
5
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
-
(2003)
BMJ
, vol.327
, pp. 557-560
-
-
Higgins, J.P.1
Thompson, S.G.2
Deeks, J.J.3
Altman, D.G.4
-
6
-
-
0028659004
-
Operating characteristics of a rank correlation test for publication bias
-
Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
-
(1994)
Biometrics
, vol.50
, Issue.4
, pp. 1088-1101
-
-
Begg, C.B.1
Mazumdar, M.2
-
7
-
-
0030922816
-
Bias in meta-analysis detected by a simple, graphical test
-
Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
-
(1997)
BMJ
, vol.315
, Issue.7109
, pp. 629-634
-
-
Egger, M.1
Davey Smith, G.2
Schneider, M.3
Minder, C.4
-
8
-
-
69149107165
-
PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
-
W64
-
Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. W64.
-
(2009)
Ann Intern Med
, vol.151
, Issue.4
, pp. 264-269
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
9
-
-
84901943115
-
On behalf of the SAVOR-TIMI 53 Steering Committee and Investigators
-
Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 Study. Poster number 5082 presented at American Heart Association, Dallas, Texas, USA on 17th November 2013.
-
Scirica BM, Raz I, Cavender MA, Steg PG, Hirshberg B, Davidson J, etal., on behalf of the SAVOR-TIMI 53 Steering Committee and Investigators. Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 Study. Poster number 5082 presented at American Heart Association 2013, Dallas, Texas, USA on 17th November 2013.
-
(2013)
-
-
Scirica, B.M.1
Raz, I.2
Cavender, M.A.3
Steg, P.G.4
Hirshberg, B.5
Davidson, J.6
-
10
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
-
(2006)
J Card Fail
, vol.12
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
11
-
-
28144441354
-
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
-
Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408.
-
(2005)
Am J Physiol Heart Circ Physiol
, vol.289
-
-
Nikolaidis, L.A.1
Elahi, D.2
Shen, Y.T.3
Shannon, R.P.4
-
12
-
-
84860390563
-
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
-
Read P.A., Hoole S.P., White P.A., Khan F.Z., O'Sullivan M., West N.E., et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011, 4(3):266-272.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, Issue.3
, pp. 266-272
-
-
Read, P.A.1
Hoole, S.P.2
White, P.A.3
Khan, F.Z.4
O'Sullivan, M.5
West, N.E.6
-
13
-
-
77951934948
-
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
-
Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010, 3:195-201.
-
(2010)
Circ Cardiovasc Imaging
, vol.3
, pp. 195-201
-
-
Read, P.A.1
Khan, F.Z.2
Heck, P.M.3
Hoole, S.P.4
Dutka, D.P.5
-
14
-
-
77950267745
-
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
-
Ban K., Kim K.H., Cho C.K., Sauvé M., Diamandis E.P., Backx P.H., et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
-
(2010)
Endocrinology
, vol.151
, pp. 1520-1531
-
-
Ban, K.1
Kim, K.H.2
Cho, C.K.3
Sauvé, M.4
Diamandis, E.P.5
Backx, P.H.6
-
15
-
-
58149335320
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
-
Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Obes Metab 2009, 11:167-176.
-
(2009)
Obes Metab
, vol.11
, pp. 167-176
-
-
Pratley, R.E.1
Kipnes, M.S.2
Fleck, P.R.3
Wilson, C.4
Mekki, Q.5
-
16
-
-
58149171060
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study
-
DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008, 31:2315-2317.
-
(2008)
Diabetes Care
, vol.31
, pp. 2315-2317
-
-
DeFronzo, R.A.1
Fleck, P.R.2
Wilson, C.A.3
Mekki, Q.4
-
17
-
-
57649225147
-
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
-
Alogliptin Study 008 Group
-
Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q., Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63(1):46-55.
-
(2009)
Int J Clin Pract
, vol.63
, Issue.1
, pp. 46-55
-
-
Nauck, M.A.1
Ellis, G.C.2
Fleck, P.R.3
Wilson, C.A.4
Mekki, Q.5
-
18
-
-
84901948754
-
-
http://clinicaltrials.gov/.
-
-
-
-
19
-
-
79951699944
-
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes
-
Rosenstock J., Inzucchi S.E., Seufert J., Fleck P.R., Wilson C.A., Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010, 33(11):2406-2408.
-
(2010)
Diabetes Care
, vol.33
, Issue.11
, pp. 2406-2408
-
-
Rosenstock, J.1
Inzucchi, S.E.2
Seufert, J.3
Fleck, P.R.4
Wilson, C.A.5
Mekki, Q.6
-
20
-
-
79953174825
-
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
-
Gomis R., Espadero R.M., Jones R., Woerle H.J., Dugi K.A. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13(7):653-661.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.7
, pp. 653-661
-
-
Gomis, R.1
Espadero, R.M.2
Jones, R.3
Woerle, H.J.4
Dugi, K.A.5
-
21
-
-
78649691630
-
Safety and efficacy of linagliptin as add- on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
-
Taskinen M.R., Rosenstock J., Tamminen I., Kubiak R., Patel S., Dugi K.A., et al. Safety and efficacy of linagliptin as add- on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:65-74.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 65-74
-
-
Taskinen, M.R.1
Rosenstock, J.2
Tamminen, I.3
Kubiak, R.4
Patel, S.5
Dugi, K.A.6
-
22
-
-
78851472527
-
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
-
Del Prato S., Barnett A.H., Huisman H., Neubacher D., Woerle H.J., Dugi K.A. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011, 13(3):258-267.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.3
, pp. 258-267
-
-
Del Prato, S.1
Barnett, A.H.2
Huisman, H.3
Neubacher, D.4
Woerle, H.J.5
Dugi, K.A.6
-
23
-
-
80053072352
-
Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
-
Owens D.R., Swallow R., Dugi K.A., Woerle H.J. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011, 28(11):1352-1361.
-
(2011)
Diabet Med
, vol.28
, Issue.11
, pp. 1352-1361
-
-
Owens, D.R.1
Swallow, R.2
Dugi, K.A.3
Woerle, H.J.4
-
24
-
-
84862813117
-
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
-
Haak T., Meinicke T., Jones R., Weber S., von Eynatten M., Woerle H.J. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012, 14(6):565-574.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.6
, pp. 565-574
-
-
Haak, T.1
Meinicke, T.2
Jones, R.3
Weber, S.4
von Eynatten, M.5
Woerle, H.J.6
-
25
-
-
84858003503
-
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
-
Kawamori R., Inagaki N., Araki E., Watada H., Hayashi N., Horie Y., et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012, 14(4):348-357.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.4
, pp. 348-357
-
-
Kawamori, R.1
Inagaki, N.2
Araki, E.3
Watada, H.4
Hayashi, N.5
Horie, Y.6
-
26
-
-
84864757433
-
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
-
Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380(9840):475-483.
-
(2012)
Lancet
, vol.380
, Issue.9840
, pp. 475-483
-
-
Gallwitz, B.1
Rosenstock, J.2
Rauch, T.3
Bhattacharya, S.4
Patel, S.5
von Eynatten, M.6
-
27
-
-
79955015666
-
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
-
CV181039 Investigators
-
Pfützner A., Paz-Pacheco E., Allen E., Frederich R., Chen R., CV181039 Investigators Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011, 13(6):567-576.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.6
, pp. 567-576
-
-
Pfützner, A.1
Paz-Pacheco, E.2
Allen, E.3
Frederich, R.4
Chen, R.5
-
28
-
-
81255160603
-
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial
-
Yang W., Pan C.Y., Tou C., Zhao J., Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011, 94(2):217-224.
-
(2011)
Diabetes Res Clin Pract
, vol.94
, Issue.2
, pp. 217-224
-
-
Yang, W.1
Pan, C.Y.2
Tou, C.3
Zhao, J.4
Gause-Nilsson, I.5
-
29
-
-
84863230449
-
Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
-
Pan C.Y., Yang W., Tou C., Gause-Nilsson I., Zhao J. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012, 28(3):268-275.
-
(2012)
Diabetes Metab Res Rev
, vol.28
, Issue.3
, pp. 268-275
-
-
Pan, C.Y.1
Yang, W.2
Tou, C.3
Gause-Nilsson, I.4
Zhao, J.5
-
30
-
-
70349333861
-
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
-
CV181-011 Study Investigators
-
Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R., CV181-011 Study Investigators Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25(10):2401-2411.
-
(2009)
Curr Med Res Opin
, vol.25
, Issue.10
, pp. 2401-2411
-
-
Rosenstock, J.1
Aguilar-Salinas, C.2
Klein, E.3
Nepal, S.4
List, J.5
Chen, R.6
-
31
-
-
79959217544
-
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
-
CV181013 Investigators
-
Hollander P.L., Li J., Frederich R., Allen E., Chen R., CV181013 Investigators Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011, 8(2):125-135.
-
(2011)
Diab Vasc Dis Res
, vol.8
, Issue.2
, pp. 125-135
-
-
Hollander, P.L.1
Li, J.2
Frederich, R.3
Allen, E.4
Chen, R.5
-
32
-
-
79959211974
-
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
-
CV181040 Investigators
-
Chacra A.R., Tan G.H., Ravichandran S., List J., Chen R., CV181040 Investigators Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011, 8(2):150-159.
-
(2011)
Diab Vasc Dis Res
, vol.8
, Issue.2
, pp. 150-159
-
-
Chacra, A.R.1
Tan, G.H.2
Ravichandran, S.3
List, J.4
Chen, R.5
-
33
-
-
79954508355
-
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
-
Barzilai N., Guo H., Mahoney E.M., Caporossi S., Golm G.T., Langdon R.B., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27(5):1049-1058.
-
(2011)
Curr Med Res Opin
, vol.27
, Issue.5
, pp. 1049-1058
-
-
Barzilai, N.1
Guo, H.2
Mahoney, E.M.3
Caporossi, S.4
Golm, G.T.5
Langdon, R.B.6
-
34
-
-
34547863123
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
-
Sitagliptin Study 035 Group
-
Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P., Sitagliptin Study 035 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9(5):733-745.
-
(2007)
Diabetes Obes Metab
, vol.9
, Issue.5
, pp. 733-745
-
-
Hermansen, K.1
Kipnes, M.2
Luo, E.3
Fanurik, D.4
Khatami, H.5
Stein, P.6
-
35
-
-
78751562877
-
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes
-
Yoon K.H., Shockey G.R., Teng R., Golm G.T., Thakkar P.R., Meehan A.G., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract 2011, 65:154-164.
-
(2011)
Int J Clin Pract
, vol.65
, pp. 154-164
-
-
Yoon, K.H.1
Shockey, G.R.2
Teng, R.3
Golm, G.T.4
Thakkar, P.R.5
Meehan, A.G.6
-
36
-
-
73349119110
-
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
-
Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(2):167-177.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.2
, pp. 167-177
-
-
Vilsbøll, T.1
Rosenstock, J.2
Yki-Järvinen, H.3
Cefalu, W.T.4
Chen, Y.5
Luo, E.6
-
37
-
-
33845476757
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
-
Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
-
(2006)
Diabetes Care
, vol.29
, pp. 2638-2643
-
-
Charbonnel, B.1
Karasik, A.2
Liu, J.3
Wu, M.4
Meininger, G.5
-
38
-
-
33751557143
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study
-
Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
-
(2006)
Clin Ther
, vol.28
, pp. 1556-1568
-
-
Rosenstock, J.1
Brazg, R.2
Andryuk, P.J.3
Lu, K.4
Stein, P.5
-
39
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
Sitagliptin Study 021 Group
-
Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E., Sitagliptin Study 021 Group Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
-
(2006)
Diabetes Care
, vol.29
, Issue.12
, pp. 2632-2637
-
-
Aschner, P.1
Kipnes, M.S.2
Lunceford, J.K.3
Sanchez, M.4
Mickel, C.5
Williams-Herman, D.E.6
-
40
-
-
84875221492
-
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
-
Fonseca V., Staels B., Morgan J.D., Shentu Y., Golm G.T., Johnson-Levonas A.O., et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complicat 2013, 27(2):177-183.
-
(2013)
J Diabetes Complicat
, vol.27
, Issue.2
, pp. 177-183
-
-
Fonseca, V.1
Staels, B.2
Morgan, J.D.3
Shentu, Y.4
Golm, G.T.5
Johnson-Levonas, A.O.6
-
41
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
-
DURATION-2 Study Group
-
Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., DURATION-2 Study Group, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376(9739):431-439.
-
(2010)
Lancet
, vol.376
, Issue.9739
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
Malloy, J.4
Walsh, B.5
Yan, P.6
-
42
-
-
39749184723
-
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
-
Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24(2):537-550.
-
(2008)
Curr Med Res Opin
, vol.24
, Issue.2
, pp. 537-550
-
-
Raz, I.1
Chen, Y.2
Wu, M.3
Hussain, S.4
Kaufman, K.D.5
Amatruda, J.M.6
-
43
-
-
78650656671
-
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
-
Arechavaleta R., Seck T., Chen Y., Krobot K.J., O'Neill E.A., Duran L., et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011, 13(2):160-168.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.2
, pp. 160-168
-
-
Arechavaleta, R.1
Seck, T.2
Chen, Y.3
Krobot, K.J.4
O'Neill, E.A.5
Duran, L.6
-
44
-
-
84859444408
-
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
-
Wainstein J., Katz L., Engel S.S., Xu L., Golm G.T., Hussain S., et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012, 14(5):409-418.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.5
, pp. 409-418
-
-
Wainstein, J.1
Katz, L.2
Engel, S.S.3
Xu, L.4
Golm, G.T.5
Hussain, S.6
-
45
-
-
33845489598
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
-
Sitagliptin Study 023 Group
-
Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H., Sitagliptin Study 023 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49(11):2564-2571.
-
(2006)
Diabetologia
, vol.49
, Issue.11
, pp. 2564-2571
-
-
Raz, I.1
Hanefeld, M.2
Xu, L.3
Caria, C.4
Williams-Herman, D.5
Khatami, H.6
-
46
-
-
84875220385
-
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial
-
Arjona Ferreira J.C., Corry D., Mogensen C.E., Sloan L., Xu L., Golm G.T., et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013, 61(4):579-587.
-
(2013)
Am J Kidney Dis
, vol.61
, Issue.4
, pp. 579-587
-
-
Arjona Ferreira, J.C.1
Corry, D.2
Mogensen, C.E.3
Sloan, L.4
Xu, L.5
Golm, G.T.6
-
47
-
-
84873465231
-
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
-
Dobs A.S., Goldstein B.J., Aschner P., Horton E.S., Umpierrez G.E., Duran L., et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diabetes 2013, 5(1):68-79.
-
(2013)
J Diabetes
, vol.5
, Issue.1
, pp. 68-79
-
-
Dobs, A.S.1
Goldstein, B.J.2
Aschner, P.3
Horton, E.S.4
Umpierrez, G.E.5
Duran, L.6
-
48
-
-
45449105789
-
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
-
Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies M.J., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10(7):545-555.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.7
, pp. 545-555
-
-
Chan, J.C.1
Scott, R.2
Arjona Ferreira, J.C.3
Sheng, D.4
Gonzalez, E.5
Davies, M.J.6
-
49
-
-
77952083721
-
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
-
Williams-Herman D., Johnson J., Teng R., Golm G., Kaufman K.D., Goldstein B.J., et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(5):442-451.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.5
, pp. 442-451
-
-
Williams-Herman, D.1
Johnson, J.2
Teng, R.3
Golm, G.4
Kaufman, K.D.5
Goldstein, B.J.6
-
50
-
-
77949387699
-
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
-
Sitagliptin Study 024 Group
-
Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., Sitagliptin Study 024 Group, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010, 64(5):562-576.
-
(2010)
Int J Clin Pract
, vol.64
, Issue.5
, pp. 562-576
-
-
Seck, T.1
Nauck, M.2
Sheng, D.3
Sunga, S.4
Davies, M.J.5
Stein, P.P.6
-
51
-
-
84881189911
-
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
-
Strain W.D., Lukashevich V., Kothny W., Hoellinger M.J., Paldánius P.M. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013, 382(9890):409-416.
-
(2013)
Lancet
, vol.382
, Issue.9890
, pp. 409-416
-
-
Strain, W.D.1
Lukashevich, V.2
Kothny, W.3
Hoellinger, M.J.4
Paldánius, P.M.5
-
52
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50(6):1148-1155.
-
(2007)
Diabetologia
, vol.50
, Issue.6
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
53
-
-
84863312882
-
Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
-
Institution Investigators
-
Pan C., Xing X., Han P., Zheng S., Ma J., Liu J., Institution Investigators, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14(8):737-744.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.8
, pp. 737-744
-
-
Pan, C.1
Xing, X.2
Han, P.3
Zheng, S.4
Ma, J.5
Liu, J.6
-
54
-
-
41749106662
-
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
-
Pan C., Yang W., Barona J.P., Wang Y., Niggli M., Mohideen P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25(4):435-441.
-
(2008)
Diabet Med
, vol.25
, Issue.4
, pp. 435-441
-
-
Pan, C.1
Yang, W.2
Barona, J.P.3
Wang, Y.4
Niggli, M.5
Mohideen, P.6
-
55
-
-
33847687205
-
Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
-
Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39(3):218-223.
-
(2007)
Horm Metab Res
, vol.39
, Issue.3
, pp. 218-223
-
-
Dejager, S.1
Razac, S.2
Foley, J.E.3
Schweizer, A.4
-
56
-
-
44949170696
-
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia
-
Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Jauffret S., et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10(8):675-682.
-
(2008)
Diabetes Obes Metab
, vol.10
, Issue.8
, pp. 675-682
-
-
Scherbaum, W.A.1
Schweizer, A.2
Mari, A.3
Nilsson, P.M.4
Lalanne, G.5
Jauffret, S.6
-
57
-
-
65549131200
-
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
-
Bolli G., Dotta F., Colin L., Minic B., Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009, 11:589-595.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 589-595
-
-
Bolli, G.1
Dotta, F.2
Colin, L.3
Minic, B.4
Goodman, M.5
-
58
-
-
58149330590
-
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
-
Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahrén B., Byiers S., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11(2):157-166.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.2
, pp. 157-166
-
-
Ferrannini, E.1
Fonseca, V.2
Zinman, B.3
Matthews, D.4
Ahrén, B.5
Byiers, S.6
-
59
-
-
65549109984
-
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
-
Rosenstock J., Niggli M., Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11(6):571-578.
-
(2009)
Diabetes Obes Metab
, vol.11
, Issue.6
, pp. 571-578
-
-
Rosenstock, J.1
Niggli, M.2
Maldonado-Lutomirsky, M.3
-
60
-
-
71849095372
-
Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes
-
Foley J.E., Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009, 41(12):905-909. 10.1055/s-0029-1234042.
-
(2009)
Horm Metab Res
, vol.41
, Issue.12
, pp. 905-909
-
-
Foley, J.E.1
Sreenan, S.2
|